What are the approved and off‑label clinical uses, dosing regimens, and contraindications of baclofen?

Baclofen: Clinical Uses, Dosing, and Contraindications

FDA-Approved Indication

Baclofen is FDA-approved specifically for the alleviation of spasticity resulting from multiple sclerosis, particularly for relief of flexor spasms, concomitant pain, clonus, and muscular rigidity, as well as spasticity from spinal cord injuries and other spinal cord diseases. 1

• Baclofen is not indicated for skeletal muscle spasm from rheumatic disorders 1
• Efficacy has not been established in stroke, cerebral palsy, or Parkinson's disease, and is therefore not recommended for these conditions 1
• Patients should have reversible spasticity where treatment will aid in restoring residual function 1

Dosing Regimens

Oral Baclofen for Spasticity

For older adults with spasticity, start with 5 mg up to three times daily, monitoring for muscle weakness, urinary dysfunction, cognitive effects, and sedation. 2

• Older persons rarely tolerate doses greater than 30-40 mg per day 2
• For chronic stroke patients, oral baclofen may reduce spasticity and pain but reportedly causes significant sedation and has less impact on spasticity compared to other conditions 3
• Tizanidine, dantrolene, and oral baclofen should be considered for spasticity resulting in pain, poor skin hygiene, or decreased function 3

Intrathecal Baclofen

Intrathecal baclofen should be considered for chronic stroke patients with spasticity causing pain, poor skin hygiene, or decreased function, particularly when oral medications are inadequate. 3

• Intrathecal baclofen is highly effective in managing spasticity in children who may suffer limb deformity, joint dislocation, and poor motor function 4
• ITB can be considered during all phases of diseases, including progressive neurologic diseases, and should not be exclusively reserved for individuals who have failed other approaches 4
• Perioperative management of patients receiving intrathecal baclofen should be planned with specialist input 5

Off-Label Use: Alcohol Use Disorder

For alcohol use disorder in patients with alcoholic liver disease, baclofen 30-60 mg/day (10 mg three times daily) is the only pharmacotherapy tested in randomized trials and showed benefit in maintaining abstinence. 6, 7, 6

• A 12-week course of baclofen (10 mg three times daily) resulted in improved rates of total alcohol abstinence and decreased relapse in patients with both compensated and decompensated cirrhosis 6
• Patients with hepatic encephalopathy were excluded from trials, as baclofen may impair mentation, a side effect potentially exacerbated in advanced liver disease 6
• Baclofen has limited hepatic metabolism and is primarily renally excreted, making it safer than naltrexone or disulfiram in liver disease 6
• Moderate-certainty evidence shows baclofen probably decreases relapse risk (RR 0.87) and increases percentage of days abstinent, particularly among detoxified participants 8

Other Off-Label Uses

Baclofen has been increasingly used off-label for musculoskeletal pain, gastroesophageal reflux disease, and as a second-line drug for paroxysmal neuropathic pain, though evidence is limited. 2, 9, 10

• For neuropathic pain, baclofen may be considered when pain has been refractory to other therapies, though data are minimal 11
• Starting with low doses and gradually increasing may minimize common side effects of dizziness, somnolence, and gastrointestinal symptoms 2

Contraindications and Critical Safety Considerations

Absolute Contraindication

Baclofen is contraindicated only in patients with hypersensitivity to baclofen, which is rare. 1, 4

• Some patients with adverse reactions to oral baclofen may be mistakenly classified as allergic and may actually benefit from intrathecal baclofen 4

Relative Contraindications

Relative contraindications include unrealistic goals, unmanageable mental health issues, psychosocial factors affecting compliance, and financial burden. 4

• Active infection is a contraindication for intrathecal baclofen 4
• Hepatic or renal dysfunction requires dose adjustment and close monitoring 2

Withdrawal Syndrome: Life-Threatening Emergency

Abrupt discontinuation of baclofen, particularly intrathecal baclofen, is potentially life-threatening and must be avoided at all costs. 5, 9

• Withdrawal symptoms include visual and auditory hallucinations, anxiety, agitation, delirium, fever, tremors, tachycardia, and seizures 5
• Abrupt withdrawal of intrathecal baclofen can cause high fever, altered mental status, rebound spasticity, and muscle rigidity leading to rhabdomyolysis, multiorgan failure, and death 5
• Perioperative recommendation: Take baclofen preoperatively including the day of operation to avoid withdrawal 5
• Baclofen withdrawal is most effectively treated with re-initiation or supplementation of baclofen dosing 9

Common Adverse Effects

Baclofen increases fatigue, dizziness, somnolence/sedation, dry mouth, paresthesia, and muscle spasms/rigidity compared to placebo. 8

• Dose-dependent sedation is a consistent concern, particularly when used with opiates or other CNS depressants 5
• Monitor for muscle weakness, urinary function, cognitive effects, and sedation 2
• When cognition is impaired, baclofen controls spasticity without the cognitive side effects of some oral medications 4

Drug Interactions

Baclofen has potential for increased sedation when used concomitantly with opiates and/or other central nervous system depressants. 5

• Close monitoring is required for renal dysfunction and worsening mental status/sedation 6

Comparative Effectiveness

High-certainty evidence shows baclofen does not increase adverse events, treatment dropouts, or dropouts due to adverse events compared to placebo. 8

• Compared to naltrexone, baclofen may increase relapse risk but the evidence is very uncertain 8
• Compared to acamprosate, one small study found no differences in outcomes but evidence was very uncertain 8